NEW YORK – BforCure, a Paris-based point-of-care diagnostics firm, said on Monday it has received the CE-IVD mark for a PCR kit to detect influenza A, influenza B, and SARS-CoV-2.
The assay, called the Bfast [Flu A/Flu B/SARS-CoV-2] RT-PCR kit - 48, is intended for laboratories processing high volumes of samples and is provided in a 48-well microplate format.
Last year, BforCure obtained the CE mark for its Chronos Dx portable qPCR thermocycler and also for a SARS-CoV-2 detection kit. The firm is developing multiple infectious disease panels for its point-of-care system. It also raised $2.3 million to adapt its platform for cancer detection.